Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5454 - First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma


Julien Taieb


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


J. Taieb1, A. Carrato2, B. Westphalen3, D. Melisi4, G. Prager5, T. Macarulla Mercade6, Å.B.C. Mellbring7, N. d'Esquermes8, A. Ferreras8, F. de Jong9

Author affiliations

  • 1 Gastroenterology And Digestive Oncology Department, Georges Pompidou European Hospital, Sorbonne Paris Cité, Paris Descartes University, 75015 - Paris/FR
  • 2 Medical Oncology, Ramón y Cajal University Hospital, Madrid/ES
  • 3 Comprehensive Cancer Center München, Klinikum der Universität München, 81377 - Munich/DE
  • 4 Medical Oncology, University of Verona, 37134 - Verona/IT
  • 5 Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 - Vienna/AT
  • 6 Medical Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 7 Oncology, Shire Sweden AB, - - Stockholm/SE
  • 8 Advanced Analytics, Genactis, Mougins/FR
  • 9 Global Medical Affairs Oncology, Shire International GmbH, Zug/CH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5454


FOLFIRINOX and GN have shown superior OS but with increased toxicity in fitter and younger pts vs gemcitabine. In routine practice, FOLFIRINOX is often modified at start (eg no 5FU bolus). No randomized phase III data are available and real world data are scarce.


In this observational electronic chart review data were retrospectively recorded of pts ≥18 y who completed 1L mPAC tx JUL14-JAN16. Physicians (HCPs) were recruited across different regions and settings and encouraged to enter pts in/beyond 2L. Baseline characteristics and outcomes of 1L FOLFIRINOX and GN are reported. Data are descriptive.


2,565 records were completed by 225 HCPs; 500–504 from FR/GER/IT/SP/UK. Of 912 1L FOLFIRINOX pts, 18% started mFOLFIRINOX. Of 748 fFOLFIRINOX pts, 26% were later dose modified. Of 660 1L GN pts, 20% were dose modified. Compared with GN, more FOLFIRINOX pts were <65 y, male and fitter (Table). Compared with fFOLFIRINOX, more mFOLFIRINOX pts were <65 y and female. Female fFOLFIRINOX pts were a little more often dose adjusted. Of FOLFIRINOX/GN pts, 12/23% stopped further tx after 1L, 10/9% were awaiting 2L and 78/67% were in ≥ 2L. mOS/mPFS in this selected population was 15/10 mo for FOLFIRINOX and 12/7 mo for GN. mFOLFIRINOX (16/10 mo) had similar outcomes vs fFOLFIRINOX (15/10 mo). On average, 1.5 reasons were reported to stop tx. Most common for FOLFIRINOX/GN were: radiological PD (39/54%), clinical PD (24/32%), tx completed as planned (36/18%) and toxicity (13/9%). No overall benefit of continued tx by pt (8%/9%) or HCP decision (7%/7%) were noted, no differences between f/mFOLFIRINOX were seen.Table: 723P

First-line treatmentN% pts with dose adjustment% pts >65 year% female pts% pts 0-1 ECOG Performance Score% pts received 2LMedian OS/PFS (months)
gemcitabine+nab-paclitaxel (GN)66020.5%44.8%43.2%76.5%67.4%12/7
fFOLFIRINOX modified in cycle 2/32725.9%48.1%92.6%66.7%
fFOLFIRINOX modified in cycle 3+16827.4%41.1%88.1%77.4%
fFOLFIRINOX never modified55324.4%32.7%86.1%78.9%


In this large retrospective chart review, pt characteristics and outcomes for 1L mPAC f/mFOLFIRINOX tx were similar. GN had somewhat lower mOS/mPFS; however, more GN pts were >65 y, female, less fit, and less received 2L tx.

Clinical trial identification

Legal entity responsible for the study




Editorial Acknowledgement

Medical writing support for the preparation of this abstract was provided by Physicians World Europe GmbH, Mannheim, Germany, with financial support from Shire (previously Baxalta), Zug, Switzerland.


J. Taieb: Honoraria, Consulting, Speaker roles: Amgen, Roche, Merck, Celgene, Shire, Lilly, Sanofi, Sirtex, Servier. A. Carrato: Advisory boards: Roche, Merck, MSD, Baxter, Shire, Celgene, Bayer. B. Westphalen: Advisory boards: Roche, Celgene, Shire, RedHill; Research support: Roche. D. Melisi: Research funding: Shire, Incyte, Celgene; Consulting role: Eli Lilly, Shire, Baxter, Incyte. G. Prager: Advisory board, Speaker fees: Shire, Celgene, Halozyme. Å.B.C. Mellbring, F. de Jong: Employee, Stockholder: Shire. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.